Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China
· Delayed Price · Currency is CNY 3.940
0.00 (0.00%)
May 16, 2025, 3:04 PM CST
SHE:002424 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 3,825 | 4,256 | 3,530 | 3,080 | 3,078 | Upgrade
|
| Other Revenue | - | 7.31 | 10.4 | 31.08 | 9.72 | Upgrade
|
| Revenue | 3,825 | 4,263 | 3,540 | 3,111 | 3,088 | Upgrade
|
| Revenue Growth (YoY) | -10.27% | 20.42% | 13.79% | 0.75% | 8.33% | Upgrade
|
| Cost of Revenue | 1,603 | 1,953 | 1,438 | 1,271 | 1,355 | Upgrade
|
| Gross Profit | 2,222 | 2,310 | 2,103 | 1,840 | 1,733 | Upgrade
|
| Selling, General & Admin | 2,083 | 2,560 | 1,747 | 1,481 | 1,355 | Upgrade
|
| Research & Development | 23.1 | 42.04 | 22.4 | 30.43 | 37 | Upgrade
|
| Other Operating Expenses | -7.16 | 40.29 | 49.21 | 39.14 | 44.03 | Upgrade
|
| Operating Expenses | 2,065 | 2,713 | 1,879 | 1,617 | 1,537 | Upgrade
|
| Operating Income | 157.26 | -402.34 | 223.43 | 222.85 | 196.54 | Upgrade
|
| Interest Expense | - | -92.71 | -101.66 | -116.26 | -131.31 | Upgrade
|
| Interest & Investment Income | - | 6.54 | 31.18 | 3.74 | 71.58 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | 0 | 0.06 | -0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.47 | -15.71 | -22.87 | -33.05 | -0.64 | Upgrade
|
| EBT Excluding Unusual Items | 158.74 | -504.22 | 130.08 | 77.33 | 136.14 | Upgrade
|
| Gain (Loss) on Sale of Investments | -35.07 | -4.3 | 9.64 | 58.53 | 31.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.14 | 1.14 | -0.3 | -0.47 | 28.97 | Upgrade
|
| Asset Writedown | -56.62 | 0.15 | -0.09 | -0.92 | -0.49 | Upgrade
|
| Other Unusual Items | - | 14.17 | 19.72 | 7.16 | 12.44 | Upgrade
|
| Pretax Income | 66.91 | -493.07 | 159.06 | 141.63 | 208.77 | Upgrade
|
| Income Tax Expense | 30.14 | -80.61 | 22.81 | 32.1 | 55.04 | Upgrade
|
| Earnings From Continuing Operations | 36.77 | -412.46 | 136.25 | 109.53 | 153.73 | Upgrade
|
| Minority Interest in Earnings | -3.14 | -2.05 | 2.23 | 8.95 | -1.35 | Upgrade
|
| Net Income | 33.62 | -414.51 | 138.47 | 118.48 | 152.38 | Upgrade
|
| Net Income to Common | 33.62 | -414.51 | 138.47 | 118.48 | 152.38 | Upgrade
|
| Net Income Growth | - | - | 16.87% | -22.24% | -46.11% | Upgrade
|
| Shares Outstanding (Basic) | 1,681 | 1,382 | 1,385 | 1,481 | 1,385 | Upgrade
|
| Shares Outstanding (Diluted) | 1,681 | 1,382 | 1,385 | 1,481 | 1,385 | Upgrade
|
| Shares Change (YoY) | 21.67% | -0.22% | -6.50% | 6.92% | -2.02% | Upgrade
|
| EPS (Basic) | 0.02 | -0.30 | 0.10 | 0.08 | 0.11 | Upgrade
|
| EPS (Diluted) | 0.02 | -0.30 | 0.10 | 0.08 | 0.11 | Upgrade
|
| EPS Growth | - | - | 25.00% | -27.27% | -45.00% | Upgrade
|
| Free Cash Flow | -33 | 21.65 | 433.7 | -100.81 | 454.39 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | 0.02 | 0.31 | -0.07 | 0.33 | Upgrade
|
| Gross Margin | 58.09% | 54.19% | 59.39% | 59.13% | 56.13% | Upgrade
|
| Operating Margin | 4.11% | -9.44% | 6.31% | 7.16% | 6.37% | Upgrade
|
| Profit Margin | 0.88% | -9.72% | 3.91% | 3.81% | 4.93% | Upgrade
|
| Free Cash Flow Margin | -0.86% | 0.51% | 12.25% | -3.24% | 14.71% | Upgrade
|
| EBITDA | 261 | -298.61 | 326.77 | 318.05 | 293.03 | Upgrade
|
| EBITDA Margin | 6.82% | -7.00% | 9.23% | 10.22% | 9.49% | Upgrade
|
| D&A For EBITDA | 103.74 | 103.74 | 103.35 | 95.2 | 96.48 | Upgrade
|
| EBIT | 157.26 | -402.34 | 223.43 | 222.85 | 196.54 | Upgrade
|
| EBIT Margin | 4.11% | -9.44% | 6.31% | 7.16% | 6.37% | Upgrade
|
| Effective Tax Rate | 45.05% | - | 14.34% | 22.66% | 26.37% | Upgrade
|
| Revenue as Reported | 3,825 | 4,263 | 3,540 | 3,111 | 3,088 | Upgrade
|
| Advertising Expenses | - | - | - | - | 92.39 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.